Abstract
Characterization of T-lymphocyte subpopulations adjacent to and infiltrating the primary tumor of breast cancer was carried out using a direct immunofluorescence procedure with the antibodies anti-(Leu-2a) for suppressor/cytotoxic (CD8+) and anti-(Leu-3a) for helper/inducer (CD4+) T-lymphocytes. Fifty-six primary malignant tumors with lymphoid infiltration were studied. The majority (58.9%) were infiltrating duct carcinoma. There were metastases to axillary lymph nodes in 6.67% of the patients. Massive lymphoid infiltration (>40 lymphocytes per ×400 microscopic field) was found in 19.6% of the tumors and moderate infiltration (20–40 lymphocytes per field) in 51.8%. In all the tumors studied there was a reversed CD4+/CD8+ ratio as compared to that found in normal peripheral blood. In 66.1% the CD4+/CD8+ ratio (helper/suppressor) was less than 1.0. The reversed ratio was due to a significant decrease in the number of helper cells (P<0.0005). The most significant drop was in the stroma area (P<0.0001) as well as in the tumor tissue (P=0.001). Of particular interest was the significant positive correlation between the age of the patients and an increased number of CD4+lymphocytes in the stroma (P=0.02). Significant negative correlations were found between a reduced number of CD4+ lymphocytes or CD4+/CD8+ ratio and several histological parameters: tumor diameter, pleomorphism, nucleus/cytoplasm ratio. There was also a significant positive correlation between the total number of CD8+ lymphocytes infiltrating the tumor tissue and the number of axillary lymph nodes with metastatic disease (P=0.03). It is suggested that the reversed ratio of CD4+/CD8+ lymphocytes may significantly affect the host/tumor immune surveillance.
Keywords: Breast Cancer, Significant Positive Correlation, Duct Carcinoma, Axillary Lymph Node, Significant Negative Correlation
References
- 1.An T, Sood U, Pietruuk T, Cummings G, Hashimoto K, Crissman J. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Am J Pathol. 1987;128:52. [PMC free article] [PubMed] [Google Scholar]
- 2.Bilik R, Mor C, Wolloch Y, Dintsman M. Histopathological high risk factors influencing the prognosis of patients with early breast cancer. Am J Surg. 1986;151:460. doi: 10.1016/0002-9610(86)90103-0. [DOI] [PubMed] [Google Scholar]
- 3.Bloom HJ, Richardson WW, Field JR. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J. 1970;1:181. doi: 10.1136/bmj.3.5716.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cantor H, Boyse EA. Functional subclasses of T-lymphocytes bearing different Ly antigens. J Exp Med. 1975;141:1376. doi: 10.1084/jem.141.6.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Dillman RO, Koziol JA, Zavanelli MI, Royston I. Immunoincompetence in cancer patients. Cancer. 1984;53:1484. doi: 10.1002/1097-0142(19840401)53:7<1484::aid-cncr2820530710>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
- 6.Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970;25:362. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- 7.Engleman EG, Benike CJ, Glickman E, Evans RL. Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man. J Exp Med. 1981;153:193. doi: 10.1084/jem.154.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Evans RL, Wall DW, Platsoucas CD, Siegal FP, Pikning SH, Testa CM, Good RA. Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. Proc Natl Acad Sci USA. 1981;78:544. doi: 10.1073/pnas.78.1.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gottlinger HG, Rieber P, Gokel JM, Lohe KL, Riethmuller G. Infiltrating mononuclear cells in human breast carcinoma: predominance of T4 monocytic cells in the tumor stroma. Int J Cancer. 1985;35:199. doi: 10.1002/ijc.2910350210. [DOI] [PubMed] [Google Scholar]
- 10.Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. J Exp Med. 1983;157:884. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Gross RL, Latty A, Williams EA, Newberne PM. Abnormal spontaneous rosette formation and rosette inhibition in lung carcinoma. N Engl J Med. 1975;292:169. doi: 10.1056/nejm197502272920901. [DOI] [PubMed] [Google Scholar]
- 12.Hamlin IM. Possible host resistance in carcinoma of the breast: a histological study. Br J Cancer. 1968;22:383. doi: 10.1038/bjc.1968.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kaszubowski PA, Husby G, Tung KSK, Williams RCG. T-lymphocyte subpopulations in peripheral and tissues of cancer patients. Cancer Res. 1980;40:4648. [PubMed] [Google Scholar]
- 14.Keller SE, Iochim HL, Pearse T, Siletti DM. Decreased T-lymphocytes in patients with mammary cancer. Am J Clin Pathol. 1976;65:445. doi: 10.1093/ajcp/65.4.445. [DOI] [PubMed] [Google Scholar]
- 15.Morgan Da, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193:1007. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
- 16.Morrison AS, Black MM, Lowe CR. Some international differences in histology and survival in breast cancer. Int J Cancer. 1973;11:261. doi: 10.1002/ijc.2910110203. [DOI] [PubMed] [Google Scholar]
- 17.Nemoto T, Han T, Minowada J, Angkur V, Rao TJ. Cell mediated immune status of breast cancer patients: evaluation by skin tests, lymphocyte stimulation and counts of rosette forming cells. J Natl Cancer Inst. 1974;53:641. doi: 10.1093/jnci/53.3.641. [DOI] [PubMed] [Google Scholar]
- 18.Rosen PP, Saigo PE, Braun DW, Weathers E, DePalo A. Predictors of recurrence in stage I (TlNoMo) breast carcinoma. Ann Surg. 1981;193:15. doi: 10.1097/00000658-198101000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Rosenberg SA. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985;75:595. [PubMed] [Google Scholar]
- 20.Rosenberg SA, Lotze MT, Muul LM, Reichert CM. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1487. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
- 21.Schroff RW, Gale RP, Fahey JL. In: B and T cell tumors: biological and clinical aspects. Vitetta E, Fox CF, editors. New York: Academic Press; 1982. p. 285. [Google Scholar]
- 22.Schroff RW, Gottlieb MS, Prince HE, Chai LL, Fahey JL. Immunological studies of homosexual men with immunodeficiency and Kaposi's sarcoma. Clin Immunol Immunopathol. 1983;27:300. doi: 10.1016/0090-1229(83)90083-1. [DOI] [PubMed] [Google Scholar]
- 23.Sen L, Borella L. Immunological rebound after cessation of long-term chemotherapy in acute lymphocytic leukaemia: changes in distribution of T and B cell population in bone marrow and peripheral blood. Br J Haematol. 1974;27:477. doi: 10.1111/j.1365-2141.1974.tb06813.x. [DOI] [PubMed] [Google Scholar]
- 24.Shimokawara I, Imamura M, Yamanaka N. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance. Cancer. 1982;49:1456. doi: 10.1002/1097-0142(19820401)49:7<1456::aid-cncr2820490724>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
- 25.Vose BM, Moore M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer. 1979;24:579. doi: 10.1002/ijc.2910240510. [DOI] [PubMed] [Google Scholar]
- 26.Whiteside TL, Miescher S, Hurlimann J, Moretta L, Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother. 1986;23:170. doi: 10.1007/BF00205646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Whittaker MG, Rees K, Clark CG. Reduced lymphocyte transformation in breast cancer. Lancet. 1971;1:892. doi: 10.1016/s0140-6736(71)92448-2. [DOI] [PubMed] [Google Scholar]
